Palisade Bio (PALI) said Friday it began dosing ulcerative colitis patients in the final cohort of its phase 1a/b study of PALI-2108.
The company said it had completed five single ascending dose cohorts and three of four multiple ascending dose cohorts, with no serious adverse events or treatment-related adverse events tied to lab results or EKGs.
Palisade Bio said it plans to report topline data in H1.
Shares of the company were up 3% in recent Friday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。